

## ASX RELEASE

### Sienna makes first appointment to Clinical Advisory Board

- US-based Urologist Dr Raoul Concepcion becomes first member of Sienna's newly formed Clinical Advisory Board

**Melbourne, Australia, 30 January 2020:** [Sienna Cancer Diagnostics Ltd \(ASX:SDX\)](#) ("Sienna" or "the Company"), is pleased to announce the appointment of Dr Raoul Concepcion as the first member of the Company's newly formed Clinical Advisory Board. Dr Concepcion is a highly qualified, Board Certified Urologist based in Nashville Tennessee. He holds an academic appointment as Assistant Clinical Professor, Department of Urology at Vanderbilt University Medical Center and was previously president of Large Urology Group Practice Association (LUGPA). His clinical interests are the diagnosis and management of genitourinary malignancies.

As outlined in the Company's recent shareholder update, Sienna is establishing the Clinical Advisory Board to enhance the profile of hTERT within the bladder cancer diagnostic community, which should drive market adoption of the hTERT test. .

Sienna's CEO and Managing Director, Carl Stubbings commented "The appointment of Dr Concepcion to our Clinical Advisory Board is an important step in boosting the adoption of hTERT in the USA. Dr Concepcion will provide an important clinical interface for Sienna by ensuring that clinicians understand the utility that hTERT can provide as an aid in the diagnosis of bladder cancer. We are looking forward to working with Raoul".

Dr Concepcion noted "I am very excited to be working with the Sienna team. My focus has always been to improve clinical outcomes for patients and believe a broader application of hTERT as a tool in the diagnosis of bladder cancer will be a major improvement".

ENDS.

**For Further Information, please contact:**

Carl Stubbings, CEO & Managing Director

Sienna Cancer Diagnostics Ltd

[cstubbings@siennadiagnostics.com.au](mailto:cstubbings@siennadiagnostics.com.au)

+61 3 8288 2141

The release of this announcement was authorised by Tony Di Pietro, Company Secretary.





### **About Sienna Cancer Diagnostics**

Sienna Cancer Diagnostics Ltd is an Australian medical technology company with operations in the United States, Europe, Asia, Latin America and Australia. Sienna's strengths lie in the identification, development and commercialisation of novel IVD technologies that satisfy an unmet clinical / market need. The Company has taken its first product, an IVD test for the biomarker hTERT, from research, through development, manufacturing, product registration, and market launch via a growing network of distribution partners.

The Company is focused on growing revenues from the existing product, increasing market access through new distribution partners, extending the applications for their hTERT test, and expanding their product offerings with the addition of new technologies into the product development pipeline.

Sienna's most recent technology acquisition was a unique technology for the capture and isolation of target analytes in liquid biopsy samples. The sample preparation technology, known as SIEN-NET™, can more accurately and rapidly prepare samples for the liquid biopsy testing of a range of clinically useful biomarkers including exosomes, lipids, proteins, and other molecular targets of interest.

### **Forward Looking Statements**

This announcement may contain forward-looking statements, which include all matters that are not historical facts. These forward-looking statements speak only as at the date of this announcement. These statements, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by forward-looking statements. Without limitation, indications of, and guidance on, future earnings and financial position and performance are examples of forward-looking statements. No representation, warranty or assurance (express or implied) is given or made by Sienna that the forward-looking statements contained in this announcement are accurate, complete, reliable, or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, each of Sienna, its related companies and their respective directors, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward-looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

For personal use only

